AXSM
Closed
Axsome Therapeutics Inc
102.97
-1.42 (-1.36%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 104.39
Day's Range: 102.46 - 106.34
Send
sign up or login to leave a comment!
When Written:
61.68
Axsome Therapeutics Inc is a biopharmaceutical company based in New York, USA. The company is focused on developing novel therapies for the treatment of central nervous system (CNS) disorders, including depression, migraine, and Alzheimer's disease.
Axsome's lead product candidate is AXS-05, which is a combination of two drugs - dextromethorphan and bupropion. The drug is being developed for the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD).
The company also has other product candidates in its pipeline, including AXS-07 for the treatment of migraine and AXS-12 for the treatment of narcolepsy.
Axsome Therapeutics was founded in 2012 and went public in 2015. The company has partnerships with various academic institutions and research organizations, including Duke University, Massachusetts General Hospital, and the National Institute of Mental Health.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Axsome's lead product candidate is AXS-05, which is a combination of two drugs - dextromethorphan and bupropion. The drug is being developed for the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD).
The company also has other product candidates in its pipeline, including AXS-07 for the treatment of migraine and AXS-12 for the treatment of narcolepsy.
Axsome Therapeutics was founded in 2012 and went public in 2015. The company has partnerships with various academic institutions and research organizations, including Duke University, Massachusetts General Hospital, and the National Institute of Mental Health.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








